Study Summary
This trial will increase access to COVID-19 testing and vaccination among underserved populations in Utah using PHM interventions and available technology.
- Coronavirus
- COVID-19, Thalidomide Syndrome
- Coronavirus Disease 2019 (COVID-19)
- COVID-19; Cardiovascular Disease
- COVID-19
- Long-haul COVID-19
- Long COVID
- COVID-19 (coronavirus disease 2019)
- Positive SARS-CoV-2 PCR Test
- Mild-to-Moderate COVID-19
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: Year 1
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
4 Treatment Groups
Text Messaging (TM) + No Patient Navigation
1 of 4
Text Message (TM) + Request (RPN)
1 of 4
Conversational Agent (CA)+ No Patient Navigation
1 of 4
Conversational Agent (CA) + Request PN (RPN)
1 of 4
Active Control
112479 Total Participants · 4 Treatment Groups
Primary Treatment: Text Messaging (TM) + No Patient Navigation · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there any remaining spots available for the trial?
"This clinical trial is currently seeking participants, with records of its posting and last update dates being available on clinicaltrials.gov. The study was originally posted to the site on 15th January 2023 and the most recent updates occurred 8th May 2023." - Anonymous Online Contributor
Could you provide an estimation of the number of participants who have agreed to join this experiment?
"Affirmative, data posted to clinicaltrials.gov indicates that the trial is actively seeking participants and was initially posted on 15 January 2023 with a subsequent update dated 8 May 2023. The study necessitates 112479 individuals at one site for enrollment." - Anonymous Online Contributor